CANDESARTAN
Prevention
Samsung Medical CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Prevention cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivaroxaban Mazandaran University of Medical Sciences | Phase 2/3 | B |
Pirfenidone Fujian Medical University Union Hospital | Phase 2 | CCC |
Alpha-Interferon Peking University People's Hospital | N/A | D |
Acetylsalicylic Acid Muhammad Hassan | D |
Same molecule, other indications
CANDESARTAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →